These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 18342286)

  • 1. [Annex V: 18-fluorodeoxyglucose positron emission tomography in the management of differentiated thyroid cancers].
    Ann Endocrinol (Paris); 2007 Dec; 68 Suppl 2():S90-3. PubMed ID: 18342286
    [No Abstract]   [Full Text] [Related]  

  • 2. Positron emission tomography in non-medullary thyroid cancer.
    Ho Shon I; Depcynzski B; Lin M; Clark JR; Wong V; Lin P; Campbell P
    ANZ J Surg; 2011 Mar; 81(3):116-24. PubMed ID: 21342381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Early detection of synchronous thyroid carcinoma and malignant melanoma by fluorodeoxyglucose positron emission tomography].
    Snen M; Decker G; Lasar Y; Pilloy W; Berchem G
    Bull Soc Sci Med Grand Duche Luxemb; 2003; (2):111-5. PubMed ID: 15544005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PET-associated incidental neoplasms of the thyroid.
    Katz SC; Shaha A
    J Am Coll Surg; 2008 Aug; 207(2):259-64. PubMed ID: 18656056
    [No Abstract]   [Full Text] [Related]  

  • 5. Is there a role for fluorine-18 fluorodeoxyglucose positron emission tomography imaging in medullary thyroid cancer?
    Kauhanen S; Schalin-Jäntti C
    Endocrine; 2012 Dec; 42(3):461-3. PubMed ID: 22798248
    [No Abstract]   [Full Text] [Related]  

  • 6. 18F-FDG PET of thyroid nodules with inconclusive cytologic results.
    Martínez-Duncker C; Hurtado-López LM
    J Nucl Med; 2006 Sep; 47(9):1555; author reply 1555-6. PubMed ID: 16954566
    [No Abstract]   [Full Text] [Related]  

  • 7. Initial experience in use of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in thyroid carcinoma patients with elevated serum thyroglobulin but negative iodine-131 whole body scans.
    Ong SC; Ng DC; Sundram FX
    Singapore Med J; 2005 Jun; 46(6):297-301. PubMed ID: 15902358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of fluorodeoxyglucose-PET in patients with differentiated thyroid carcinoma.
    Zuijdwijk MD; Vogel WV; Corstens FH; Oyen WJ
    Nucl Med Commun; 2008 Jul; 29(7):636-41. PubMed ID: 18528186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of F-18-fluorodeoxyglucose positron emission tomography in the postoperative evaluation of differentiated thyroid cancer.
    Alzahrani AS; Abouzied ME; Salam SA; Mohamed G; Rifai A; Al Sugair A; Amin T
    Eur J Endocrinol; 2008 May; 158(5):683-9. PubMed ID: 18426827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A surgical perspective on positron emission tomography.
    Gulec SA
    J Surg Oncol; 2007 May; 95(6):443-6. PubMed ID: 17221861
    [No Abstract]   [Full Text] [Related]  

  • 11. Metastatic malignant melanoma to the thyroid gland detected by FDG-PET imaging.
    Basu S; Alavi A
    Clin Nucl Med; 2007 May; 32(5):388-9. PubMed ID: 17452870
    [No Abstract]   [Full Text] [Related]  

  • 12. Value of Fluorodeoxyglucose PET/Computed Tomography Patient Management and Outcomes in Thyroid Cancer.
    Ciarallo A; Marcus C; Taghipour M; Subramaniam RM
    PET Clin; 2015 Apr; 10(2):265-78. PubMed ID: 25829091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation of thyroid, head, and neck cancers with PET.
    Zhuang H; Kumar R; Mandel S; Alavi A
    Radiol Clin North Am; 2004 Nov; 42(6):1101-11, viii. PubMed ID: 15488560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of thyroid malignancy in a hot nodule by fluorine-18-fluorodeoxyglucose positron emission tomography.
    Low SC; Sinha AK; Sundram FX
    Singapore Med J; 2005 Jun; 46(6):304-7. PubMed ID: 15902360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluor-18-deoxyglucose positron emission tomography in differentiated thyroid cancer.
    Feine U
    Eur J Endocrinol; 1998 May; 138(5):492-6. PubMed ID: 9625358
    [No Abstract]   [Full Text] [Related]  

  • 16. F-18 FDG PET/CT demonstration of an adrenal metastasis in a patient with anaplastic thyroid cancer.
    Iagaru A; McDougall IR
    Clin Nucl Med; 2007 Jan; 32(1):13-5. PubMed ID: 17179796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDG uptake in metastatic spreading mucoepidermoid carcinoma of the thyroid.
    Wissmeyer M; Weidner S; Muggli B; Weimann R; Juengling FD; Krause T
    Clin Nucl Med; 2007 May; 32(5):383-7. PubMed ID: 17452869
    [No Abstract]   [Full Text] [Related]  

  • 18. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer.
    Lind P; Kohlfürst S
    Semin Nucl Med; 2006 Jul; 36(3):194-205. PubMed ID: 16762610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The value of FDG-PET in the follow-up of differentiated thyroid cancer: a review of the literature.
    Stokkel MP; Duchateau CS; Dragoiescu C
    Q J Nucl Med Mol Imaging; 2006 Mar; 50(1):78-87. PubMed ID: 16557207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nuclear medicine in the assessment of differentiated thyroid cancer.
    Rutherford GC; Franc B; O'Connor A
    Clin Radiol; 2008 Apr; 63(4):453-63. PubMed ID: 18325367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.